Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Weinig invloed COVID-19 op overleving kankerpatiënten
sep 2023 | Borstkanker, Bot en wekedelentumoren, Dermato-oncologie, Gynaecologische oncologie, Leukemie, Longoncologie, Lymfoom, Maag-darm-leveroncologie, Uro-oncologie